Paris

Sanofi makes $270M bet that a startup’s AI tech can boost its cancer drug R&D

The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the Sanofi investment boosts the startup into unicorn status and marks the start of its Series B funding round.

Already allied with Takeda, Egle raises €40M for its ‘starving’ immunotherapy

In less than two years, Egle Therapeutics launched, partnered with Takeda Pharmaceutical, and found its first cancer targets. Now the startup has €40M in Series A financing to further develop its new approach to modulating regulatory T cells as a way of treating autoimmune diseases and cancer.

Sanofi’s mRNA strategy adds biggest piece yet with $3.2B Translate Bio buyout

Sanofi is acquiring Translate Bio, its messenger RNA R&D partner for the past three years, in a $3.2 billion deal. The pharmaceutical and vaccines giant said the acquisition will speed up development of partnered vaccine programs and spark work on new ones in areas such as cancer, immunology, and rare diseases.

Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain

Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.

Sanofi, GSK nab $2.1B deal from federal government to provide Covid-19 vaccine

The companies will provide 100 million doses of their jointly developed vaccine. But with a Phase I/II study planned in September, it is behind in development compared with those of Moderna and Pfizer and BioNTech, which have already started late-stage clinical testing.

Two years after reset, Withings turns focus to remote patient monitoring with $60M raise

After Withings co-founder Eric Carreel bought the connected device company back from Nokia two years ago, the company has charted a more clinical course. With $60 million in new funding, Withings plans to build out a remote monitoring program for its medical devices.